Among 10,872 isolates of Enterobacteriaceae from a nationwide study of 88 French hospitals in 2005, 169 (1.7%) expressed an extended-spectrum -lactamase. The most prevalent species were Escherichia coli (48.5%), Enterobacter aerogenes (23.7%), and Klebsiella pneumoniae (14.8%). Molecular analysis underlined the polyclonal spread of CTX-M-expressing E. coli, primarily isolates of the CTX-M-1 subgroup.Resistance to extended-spectrum cephalosporins in Enterobacteriaceae can be associated with the production of extendedspectrum -lactamases (ESBL) (11). Since the end of the 1990s, a new family of ESBL, the CTX-M-type -lactamases, has spread worldwide. To date, over 60 CTX-M-type -lactamases have been described and divided into five different clusters: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 (2,17,20). Several local or regional studies indicate the emergence of CTX-M -lactamases in France, but concurring data for the nation as a whole are lacking (1,9,(12)(13)(14)(15)(16). We have conducted a nationwide prospective study in 88 nonteaching hospitals affiliated with the Collège de Bactériologie-Virologie-Hygiène des Hôpitaux de France network to evaluate both (i) the prevalence of ESBL-producing Enterobacteriaceae by using phenotypic confirmatory tests and (ii) the prevalence and molecular epidemiology of CTX-M-harboring Enterobacteriaceae (5, 6).Bacterial isolates. All ESBL-producing Enterobacteriaceae isolates were collected from clinical samples during a 1-month period (October 2005). For patients with recurrent infections, only isolates from the first episodes were included. Bacterial identification and ESBL screening were performed by the participating institutions according to the recommendations of the Antibiogram Committee of the French Society of Microbiology (10). The data concerning the total number of Enterobacteriaceae isolates and all the ESBL-producing Enterobacteriaceae isolates were centralized at the Service d'Hygiène Hospitalière, Centre Hospitalier de Versailles.Quality controls. The following four E. coli isolates were submitted anonymously: a wild type, two isolates harboring an extended-spectrum TEM or CTX-M -lactamase, and an isolate overexpressing a cephalosporinase. Analyses of the capacity of each participating institution to detect the ESBL phenotype were sent to the central laboratory.Identification and antimicrobial susceptibility testing. Analysis at the central laboratory confirmed the identification and ESBL production determined by the API 20E and VITEK 2 systems (bioMérieux, Marcy l'Etoile, France), the double-disc synergy test, the MicroScan ESBL plus ESBL confirmation panel (Dade Behring, Sacramento, CA), and the Etest ESBL (AB Biodisk, Piscataway, NJ). Non--lactam antimicrobial susceptibility testing was performed by using disk diffusion according to the French guidelines (for nalidixic acid, ciprofloxacin, gentamicin, amikacin, and cotrimoxazole) (10).PCR amplification. bla CTX-M genes were amplified by using PCR, as described previously (9). The determination of su...